N-(2-{2-[5-bromo-2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino]-5-chloropyrimidin-4-ylamino}-4-vinylphenyl)-N-methylmethanesulfonamide | 1352244-37-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-(2-{2-[5-bromo-2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino]-5-chloropyrimidin-4-ylamino}-4-vinylphenyl)-N-methylmethanesulfonamide
• 英文别名: N-(2-{2-[5-Bromo-2-methoxy-4-(4-methyl-piperazin-1-yl)-phenylamino]-5-chloro-pyrimidin-4-ylamino}-4-vinyl-phenyl)-N-methyl-methanesulfonamide；N-[2-[[2-[5-bromo-2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5-chloropyrimidin-4-yl]amino]-4-ethenylphenyl]-N-methylmethanesulfonamide
• CAS: 1352244-37-1
• 化学式: C₂₆H₃₁BrClN₇O₃S
• 分子量: 637.0
• InChiKey: KMHXSTQXBBNYIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  39
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  111
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  N-(2-{2-[5-bromo-2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino]-5-chloropyrimidin-4-ylamino}-4-vinylphenyl)-N-methylmethanesulfonamide 在 palladium diacetate 三(邻甲基苯基)磷 、 三乙胺 作用下， 以 乙腈 为溶剂， 反应 0.5h， 以72%的产率得到(14Z)-6-chloro-10-(2-methanesulfonyl-methyl-amino)-17-(4-methylpiperazin-1-yl)-19-methoxy-2,4,8,22-tetraazatetracyclo[14.3.1.1(3,7).1(9,13)]docosa-1(20),3(22),4,6,9(21),10,12,14,16,18-decaene
  参考文献：
  名称：

  [EN] MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS
  [FR] COMPOSÉS MACROCYLCIQUES COMME INHIBITEURS D'ALK, DE FAK ET DE JAK2

  摘要：

  本发明提供了式I的化合物或其药用可接受的盐形式，其中R1、R2、R3、R4、R5、A和X如本文所定义，以及其治疗方法和用途。

  公开号：

  WO2012125603A1
• 作为产物：
  描述：

  1-(2-bromo-5-methoxy-4-nitrophenyl)-4-methylpiperazine 在 甲烷磺酸 、 一水合肼 作用下， 以 乙醇 、 甲乙醚 为溶剂， 反应 5.0h， 生成 N-(2-{2-[5-bromo-2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino]-5-chloropyrimidin-4-ylamino}-4-vinylphenyl)-N-methylmethanesulfonamide
  参考文献：
  名称：

  Design, Synthesis, and Anaplastic Lymphoma Kinase (ALK) Inhibitory Activity for a Novel Series of 2,4,8,22-Tetraazatetracyclo[14.3.1.1^3,7.1^9,13]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene Macrocycles

  摘要：

  A novel set of 2,4,8,22-tetraazatetracyclo[14.3.1.1(3,7).1(9,13)]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles were prepared as potential anaplastic lymphoma kinase (ALK) inhibitors, designed to rigidly lock an energy-minimized bioactive conformation of the diaminopyrimidine (DAP) scaffold, a well-documented kinase platform. From 13 analogues prepared, macrocycle 2m showed the most promising in vitro ALK enzymatic (IC50 = 0.5 nM) and cellular (IC50 = 10 nM) activities. In addition, macrocycle 2m exhibited a favorable kinase selectivity preference for inhibition of ALK relative to the highly homologous insulin receptor (IR) kinase (IR/ALK ratio of 173). The inclusive in vitro biological results for this set of macrocycles validate this scaffold as a viable kinase template and further corroborate recent DAP/ALK solid state studies indicating that the inverted "U" shaped conformation of the acyclic DAPs is a preferred bioactive conformation.

  DOI：

  10.1021/jm201333e

文献信息

• Macrocyclic Compounds as ALK, FAK and JAK2 Inhibitors
  申请人：Cephalon, Inc.

  公开号：US20140031351A1

  公开（公告）日：2014-01-30

  The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.

  本发明提供了I式化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A和X的定义如本文所述，以及其治疗方法和用途。
• MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS
  申请人：Cephalon, Inc.

  公开号：EP2686323A1

  公开（公告）日：2014-01-22
• US9487529B2
  申请人：——

  公开号：US9487529B2

  公开（公告）日：2016-11-08